Myriad Genetics (MYGN) Competitors

Amicus Therapeutics (NASDAQ:FOLD) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Do analysts prefer FOLD or MYGN?

Amicus Therapeutics currently has a consensus target price of $16.22, suggesting a potential upside of 118.92%. Myriad Genetics has a consensus target price of $12.45, suggesting a potential upside of 118.12%. Given Amicus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Amicus Therapeutics is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amicus Therapeutics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Myriad Genetics	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Do institutionals & insiders hold more shares of FOLD or MYGN?

99.0% of Myriad Genetics shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has more risk & volatility, FOLD or MYGN?

Amicus Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500.

Is FOLD or MYGN more profitable?

Amicus Therapeutics has a net margin of -6.67% compared to Myriad Genetics' net margin of -47.45%. Amicus Therapeutics' return on equity of -5.07% beat Myriad Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amicus Therapeutics	-6.67%	-5.07%	-1.23%
Myriad Genetics	-47.45%	-5.17%	-3.44%

Does the media refer more to FOLD or MYGN?

In the previous week, Myriad Genetics had 11 more articles in the media than Amicus Therapeutics. MarketBeat recorded 17 mentions for Myriad Genetics and 6 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.29 beat Myriad Genetics' score of 0.32 indicating that Amicus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amicus Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	3 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has preferable valuation and earnings, FOLD or MYGN?

Amicus Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amicus Therapeutics	$571.16M	4.00	-$56.11M	-$0.12	-61.75
Myriad Genetics	$837.60M	0.63	-$127.30M	-$4.28	-1.33

Summary

Amicus Therapeutics beats Myriad Genetics on 11 of the 16 factors compared between the two stocks.